Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability

Journal of Clinical Oncology

Volumn 21, Issue 20, 2003, Pages 3729-3736

  Ward, Robyn Lynne ^a   Cheong, Kay ^a   Ku, Su Lyn ^a   Meagher, Alan ^a   O'Connor, Terence ^a   Hawkins, Nicholas John ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MLH1; PROTEIN P16; DNA; MICROSATELLITE DNA;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; FEMALE; FOLLOW UP; GENE LOCUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; COLORECTAL TUMOR; DNA DAMAGE; GENETICS; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; COLORECTAL NEOPLASMS; DNA DAMAGE; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0142087630     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.03.123     Document Type: Article

References (53)

1. Hermanek P, Sobin LH: TNM: American Joint Committee on Cancer-Manual for Staging of Cancer. Philadelphia, PA, Springer Verlag, 1998
2. Compton C, Fenoglio-Preiser CM, Pettigrew N, et al: American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88:1739-1757, 2000
3. Hermanek P, Wittekind C: Residual tumor (R) classification and prognosis. Semin Surg Oncol 10:12-20, 1994
4. Newland RC, Dent OF, Chapuis PH, et al: Clinicopathologically diagnosed residual tumor after resection for colorectal cancer: A 20-year prospective study. Cancer 72:1536-1542, 1993
5. Petersen S, Thames HD, Nieder C, et al: The results of colorectal cancer treatment by p53 status: Treatment-specific overview. Dis Colon Rectum 44:322-333, 2001
6. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: The "RASCAL II" study. Br J Cancer 85:692-696, 2001
7. Jen J, Kim H, Piantadosi S, et al: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331:213-221, 1994
8. Dix BR, Robbins P, Soong R, et al: The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 59:747-751, 1994
9. Sun XF, Carstensen JM, Stal O, et al: c-erbB-2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma. APMIS 103:309-315, 1995
10. Augenlicht LH, Wadler S, Corner G, et al: Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: A frequent. p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57:1769-1775, 1997
11. Pasche B, Mulcahy M, Benson AB III: Molecular markers in prognosis of colorectal cancer and prediction of response to treatment. Best Pract Res Clin Gastroenterol 16:331-345, 2002
12. Watson P, Lin KM, Rodriguez-Bigas MA, et al: Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer 83:259-266, 1998
13. Gryfe R, Kim H, Hsieh ET, et al: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:69-77, 2000
14. Wright CM, Dent OF, Barker M, et al: Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 87:1197-1202, 2000
15. Elsaleh H, Powell B, McCaul K, et al: P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7:1343-1349, 2001
16. Veigl ML, Kasturi L, Olechnowicz J, et al: Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A 95:8698-8702, 1998
17. Herman JG, Umar A, Polyak K, et al: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95:6870-6875, 1998
18. Furukawa T, Konishi F, Masubuchi S, et al: Densely methylated MLH1 promoter correlates with decreased mRNA expression in sporadic colorectal cancers. Genes Chromosomes Cancer 35:1-10, 2002
19. Menigatti M, Di Gregorio C, Borghi F, et al: Methylation pattern of different regions of the MLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer. Genes Chromosomes Cancer 31:357-361, 2001
20. Ahuja N, Mohan AL, Li Q, et al: Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 57:3370-3374, 1997
21. Toyota M, Ahuja N, Ohe-Toyota M, et al: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96:8681-8686, 1999
22. Toyota M, Ohe-Toyota M, Ahuja N, et al: Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A 97:710-715, 2000
23. Hawkins N, Norrie M, Cheong K, et al: CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122:1376-1387, 2002
24. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
25. O'Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997
26. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879-1887, 1993
27. Glimelius B: Radiotherapy in rectal cancer. Br Med Bull 64:141-157, 2002
28. Ward R, Meagher A, Tomlinson I, et al: Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 48:821-829, 2001
29. Herman JG, Graff JR, Myohanen S, et al: Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821-9826, 1996
30. Suter C, Norrie M, Ku S, et al: CpG island methylation is a common finding in colorectal cancer cell lines. Br J Cancer 88:413-419, 2003
31. Deng G, Chen A, Hong J, et al: Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 59:2029-2033, 1999
32. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354, 2000
33. Kane MF, Loda M, Gaida GM, et al: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57:808-811, 1997
34. Esteller M, Silva JM, Dominguez G, et al: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564-569, 2000
35. Tamura G, Yin J, Wang S, et al: E-cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 92:569-573, 2000
36. Esteller M, Gonzalez S, Risques RA, et al: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 19:299-304, 2001
37. Esteller M, Toyota M, Sanchez-Cespedes M, et al: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60:2368-2371, 2000
38. Zheng S, Chen P, McMillan A, et al: Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis 21:2057-2064, 2000
39. Esteller M, Tortola S, Toyota M, et al: Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60:129-133, 2000
40. Fearon ER: BRCA1 and E-cadherin promoter hypermethylation and gene inactivation in cancer-association or mechanism? J Natl Cancer Inst 92:515-517, 2000
41. Costello JF, Plass C: Methylation matters. J Med Genet 38:285-303, 2001
42. Toyota M, Ho C, Ohe-Toyota M, et al: Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5′ CpG island in human tumors. Cancer Res 59:4535-4541, 1999
43. Costello JF, Fruhwald MC, Smiraglia DJ, et al: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132-138, 2000
44. Halling KC, French AJ, McDonnell SK, et al: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 91:1295-1303, 1999
45. Elsaleh H, Joseph D, Grieu F, et al: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355:1745-1750, 2000
46. Johannsdottir JT, Bergthorsson JT, Gretarsdottir S, et al: Replication error in colorectal carcinoma: Association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. Anticancer Res 19:1821-1826, 1999
47. Salahshor S, Kressner U, Fischer H, et al: Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer 81:190-193, 1999
48. Messerini L, Ciantelli M, Baglioni S, et al: Prognostic significance of microsatellite instability in sporadic mucinous colorectal cancers. Hum Pathol 30:629-634, 1999
49. Hawkins NJ, Ward RL: Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst 93:1307-1313, 2001
50. Tomlinson I, Bodmer W: Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog. Nat Med 5:11-12, 1999
51. Quinn E, Hawkins N, Yip L, et al: CD103+ intraepithelial lymphocytes: A unique population in microsatellite unstable sporadic colorectal cancer. Eur J Cancer 39:469-475, 2003
52. Whitehall VL, Wynter CV, Walsh MD, et al: Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res 62:6011-6014, 2002
53. Smyrk TC, Watson P, Kaul K, et al: Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 91:2417-2422, 2001